Mr. Mark S. Wilson is the co-founder and CEO of MatriSys Bioscience. He is a broadly skilled bioentrepreneur with 30 years of experience in biopharmaceutical and diagnostics development with extensive accomplishments in pharmaceutical licensing and business development, new organization startup, strategic alliance formation with Big Pharma and Big Biotech firms, and developmental sourcing in a virtual company environment.
Therapeutics at the interface of the innate immune system and the skin microbiome
MatriSys Bioscience is commercializing skin microbiome therapeutics. We will describe the science behind the products, our product portfolio, and provide an update on our clinical developments.
Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the microbiome field: